NASDAQ:NARI Inari Medical (NARI) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free NARI Stock Alerts $50.00 -0.69 (-1.36%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$49.77▼$52.1050-Day Range$37.11▼$50.6952-Week Range$36.73▼$71.85Volume716,890 shsAverage Volume915,217 shsMarket Capitalization$2.91 billionP/E RatioN/ADividend YieldN/APrice Target$65.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Inari Medical alerts: Email Address Inari Medical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside31.4% Upside$65.71 Price TargetShort InterestBearish9.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 22 Articles This WeekInsider TradingSelling Shares$8.91 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector345th out of 928 stocksSurgical & Medical Instruments Industry43rd out of 100 stocks 4.4 Analyst's Opinion Consensus RatingInari Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInari Medical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Inari Medical's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.79% of the float of Inari Medical has been sold short.Short Interest Ratio / Days to CoverInari Medical has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inari Medical has recently increased by 9.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInari Medical does not currently pay a dividend.Dividend GrowthInari Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NARI. Previous Next 2.3 News and Social Media Coverage News SentimentInari Medical has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Inari Medical this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for NARI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Inari Medical to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,909,434.00 in company stock.Percentage Held by Insiders10.60% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inari Medical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inari Medical are expected to grow in the coming year, from ($0.41) to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inari Medical is -121.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inari Medical is -121.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInari Medical has a P/B Ratio of 6.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inari Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… About Inari Medical Stock (NASDAQ:NARI)Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Read More NARI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NARI Stock News HeadlinesMay 31 at 9:26 AM | insidertrades.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) CEO Sells 3,000 Shares of StockMay 22, 2024 | insidertrades.comInari Medical, Inc. (NASDAQ:NARI) Director Sells $43,755.96 in StockMay 19, 2024 | insidertrades.comWilliam Hoffman Sells 40,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockMay 17, 2024 | insidertrades.comMitch C. Hill Sells 6,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockMay 16, 2024 | insidertrades.comInari Medical, Inc. (NASDAQ:NARI) CFO Mitch C. Hill Sells 6,000 SharesMay 4, 2024 | insidertrades.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells $1,619,058.00 in StockJune 2 at 4:32 AM | americanbankingnews.comInari Medical, Inc. (NASDAQ:NARI) Director Sells $3,007,800.00 in StockJune 1 at 7:02 AM | americanbankingnews.comAndrew Hykes Sells 3,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockMay 31 at 10:45 PM | prnewswire.comINARI MEDICAL SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inari Medical, Inc. - NARIMay 31 at 4:59 PM | prnewswire.comNARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud LawsuitMay 30 at 4:13 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Inari Medical, Inc. - NARIMay 30 at 5:45 AM | prnewswire.comInvestors who lost money on Inari Medical, Inc.(NARI) should contact Levi & Korsinsky about pending Class Action - NARIMay 30 at 2:14 AM | americanbankingnews.comAnalysts Set Inari Medical, Inc. (NASDAQ:NARI) PT at $65.71May 29, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Inari Medical, Inc.(NARI) of a Class Action Lawsuit and an Upcoming DeadlineMay 29, 2024 | prnewswire.comShareholders that lost money on Inari Medical, Inc.(NARI) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreMay 28, 2024 | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inari Medical, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NARIMay 28, 2024 | businesswire.comNARI Stockholder Reminder: Contact Robbins for Information About the Inari Medical, Inc. Class ActionMay 27, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Inari Medical, Inc. with Losses to Contact the FirmMay 27, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Inari MedicalMay 26, 2024 | prnewswire.comClass Action Announcement for Inari Medical, Inc. (NARI): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Inari Medical, Inc.May 25, 2024 | markets.businessinsider.comDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Inari Medical, Inc. with Losses to Contact the FirmMay 24, 2024 | prnewswire.comINARI MEDICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inari Medical, Inc. - NARIMay 24, 2024 | finanznachrichten.deInari Medical, Inc.: Inari Medical Files Patent Infringement Lawsuit Against Imperative Care and Truvic MedicalMay 24, 2024 | prnewswire.comNARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud LawsuitMay 23, 2024 | markets.businessinsider.comGrabar Law Office Is Investigating Claims on Behalf of Current Long-term Shareholders of Inari Medical, Inc. (NARI)See More Headlines Receive NARI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/30/2024Today6/02/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NARI CUSIPN/A CIK1531048 Webwww.inarimedical.com Phone877-923-4747FaxN/AEmployees1,300Year FoundedN/APrice Target and Rating Average Stock Price Target$65.71 High Stock Price Target$84.00 Low Stock Price Target$50.00 Potential Upside/Downside+31.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,640,000.00 Net Margins-4.54% Pretax Margin-2.04% Return on Equity-1.65% Return on Assets-1.23% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.19 Sales & Book Value Annual Sales$493.63 million Price / Sales5.89 Cash Flow$0.09 per share Price / Cash Flow567.06 Book Value$7.69 per share Price / Book6.50Miscellaneous Outstanding Shares58,140,000Free Float51,975,000Market Cap$2.91 billion OptionableOptionable Beta0.93 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Andrew J. Hykes (Age 51)CEO, President & Director Comp: $1.54MMr. Mitchell C. Hill (Age 65)Chief Financial Officer Comp: $864.63kDr. Thomas M. Tu M.D. (Age 51)Chief Medical Officer Comp: $865.63kMr. Paul A. Koehn (Age 61)Senior Vice President of Operations Mr. Kevin StrangeSenior Vice President of Finance, Accounting, Strategy & Business DevelopmentMr. John Hsu C.F.A.Vice President of Investor RelationsMs. Angela AhmadGeneral Counsel & SecretaryMr. Eric KhairySenior Vice President of MarketingMr. Tim BennerSenior VP of Sales & Senior VP of U.S. SalesMs. Tara DunnSenior VP & GM of LimFlowMore ExecutivesKey CompetitorsCantel MedicalNYSE:CMDNuVasiveNASDAQ:NUVASolventumNYSE:SOLVTeleflexNYSE:TFXGlobus MedicalNYSE:GMEDView All CompetitorsInsiders & InstitutionsWilliam HoffmanSold 60,000 sharesTotal: $3.01 M ($50.13/share)Andrew HykesSold 3,000 sharesTotal: $150,000.00 ($50.00/share)Rebecca ChambersSold 964 sharesTotal: $43,755.96 ($45.39/share)iA Global Asset Management Inc.Bought 42,680 shares on 5/17/2024Ownership: 0.166%Motley Fool Asset Management LLCBought 21,582 shares on 5/17/2024Ownership: 0.113%View All Insider TransactionsView All Institutional Transactions NARI Stock Analysis - Frequently Asked Questions Should I buy or sell Inari Medical stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NARI shares. View NARI analyst ratings or view top-rated stocks. What is Inari Medical's stock price target for 2024? 7 Wall Street analysts have issued 12 month target prices for Inari Medical's stock. Their NARI share price targets range from $50.00 to $84.00. On average, they predict the company's stock price to reach $65.71 in the next year. This suggests a possible upside of 31.4% from the stock's current price. View analysts price targets for NARI or view top-rated stocks among Wall Street analysts. How have NARI shares performed in 2024? Inari Medical's stock was trading at $64.92 at the start of the year. Since then, NARI shares have decreased by 23.0% and is now trading at $50.00. View the best growth stocks for 2024 here. When is Inari Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our NARI earnings forecast. How were Inari Medical's earnings last quarter? Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Tuesday, April, 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.15. The company had revenue of $143.19 million for the quarter, compared to analyst estimates of $138.32 million. Inari Medical had a negative net margin of 4.54% and a negative trailing twelve-month return on equity of 1.65%. What ETFs hold Inari Medical's stock? ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), Tema Cardiovascular and Metabolics ETF (HRTS), Clough Select Equity ETF (CBSE), Invesco S&P SmallCap Health Care ETF (PSCH), Clough Long/Short Equity ETF (CBLS), SPDR S&P Health Care Equipment ETF (XHE) and AlphaMark Actively Managed Small Cap ETF (SMCP). What guidance has Inari Medical issued on next quarter's earnings? Inari Medical updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $592.5 million-$602.5 million, compared to the consensus revenue estimate of $588.4 million. What other stocks do shareholders of Inari Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY). When did Inari Medical IPO? Inari Medical (NARI) raised $110 million in an initial public offering on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers. Who are Inari Medical's major shareholders? Inari Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.63%), Bamco Inc. NY (1.34%), Brown Capital Management LLC (0.90%), Price T Rowe Associates Inc. MD (0.64%), Jennison Associates LLC (0.59%) and Principal Financial Group Inc. (0.53%). Insiders that own company stock include Andrew Hykes, Donald B Milder, Mitch C Hill, Mitch C Hill, Rebecca Chambers, Stanley Tang, Thomas Tu and William Hoffman. View institutional ownership trends. How do I buy shares of Inari Medical? Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NARI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsLEAKED: Jeff Bezos' $330 Million GambleBehind the MarketsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inari Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.